Cancer & Tumors434 citations
Effect of human mesenchymal stem cell transplantation on cerebral ischemic volume-controlled photothrombotic mouse model
Bioeffects Seen
Choi Y-K, Urnukhsaikhan E, Yoon H-H, Seo Y-K, Park J-K · 2016
Insufficient information to determine key finding.
Plain English Summary
Summary written for general audiences
This study is not an EMF health effects study. It examined the effects of human mesenchymal stem cell transplantation in a mouse model of cerebral ischemia induced by photothrombosis. The research focused on stem cell therapeutic potential for stroke-related brain injury rather than electromagnetic field exposure.
Why This Matters
This study belongs to regenerative medicine and stroke research literature, not EMF health effects research. It evaluates a potential cell-based therapeutic intervention for acute cerebral ischemia in an animal model.
Exposure Information
Specific exposure levels were not quantified in this study.
Cite This Study
Choi Y-K, Urnukhsaikhan E, Yoon H-H, Seo Y-K, Park J-K (2016). Effect of human mesenchymal stem cell transplantation on cerebral ischemic volume-controlled photothrombotic mouse model.
Show BibTeX
@article{choi_y_k_urnukhsaikhan_e_yoon_h_h_seo_y_k_park_j_k_ce4321,
author = {Choi Y-K and Urnukhsaikhan E and Yoon H-H and Seo Y-K and Park J-K},
title = {Effect of human mesenchymal stem cell transplantation on cerebral ischemic volume-controlled photothrombotic mouse model},
year = {2016},
doi = {10.1158/2159-8290.CD-15-0913},
}Quick Questions About This Study
Histiocytic neoplasms are rare blood disorders where abnormal immune cells (dendritic cells or macrophages) accumulate in tissues. They include Langerhans cell histiocytosis and non-Langerhans cell histiocytosis, both challenging to treat.
BRAFV600E mutations occur in about 50% of patients and provided the first targeted treatment option. However, patients without this mutation needed different therapeutic approaches, which this study helped identify.
Researchers found kinase fusions involving BRAF, ALK, and NTRK1 genes, plus activating mutations in MAP2K1 and ARAF. These discoveries opened new treatment pathways for previously difficult-to-treat patients.
Yes, patients with MAP2K1 mutations responded to MEK inhibitors, while those with ARAF mutations responded to RAF inhibitors like sorafenib. This demonstrated the value of precision medicine approaches.
Different patients have different genetic drivers of their disease. Comprehensive analysis identifies which specific mutations are present, allowing doctors to select the most effective targeted therapy for each individual patient.